Herbert A. Eradat, MD, MS

University of California, Los Angeles
$25,000 Tower Career Development Grant

Research Title:
Defining the Molecular Correlates that Determine Activity of Pan-PIM Inhibitor, SGI-1776

PIM kinases are oncogenes that are known to cause lymphomas. Our laboratory was the first to show that PIM-1 predicts shorter survival in aggressive lymphomas and we are currently conducting the first trial of a pill that inactivates PIM kinases.

The core of this grant proposal is defining the molecular characteristics that will determine the activity of the PIM inhibitor SGI-1776 in lymphomas. In addition, we will test another target (cyclin D1) for its ability to collaborate with PIM kinases in causing lymphomas. This research may lay the foundation of novel combination treatment strategies.